To appraise the clinical and cost-effectiveness of Mirvetuximab soravtansine within its marketing authorisation ovarian cancer, peritoneal cancer, or fallopian tube cancer
Topic is suspended
- Status:
- Suspended
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1527
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 March 2021 | Note added to the project documents |
| 05 March 2021 | Suspended. Topic is suspended |
| 20 May 2019 | Note added to the project documents |
| 02 May 2019 | In progress. Referred on 27 June 2018 |
For further information on our processes and methods, please see our CHTE processes and methods manual